Correction: Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma

Davide Valentini; Martin Rao; Qingda Meng; Anna von Landenberg; Jiri Bartek Jr; Georges Sinclair; Georgia Paraschoudi; Elke Jäger; Inti Harvey-Peredo; Ernest Dodoo; Markus Maeurer

doi:10.18632/oncotarget.26447

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma

PDF | How to cite

Oncotarget. 2018; 9:36817-36817. https://doi.org/10.18632/oncotarget.26447

Metrics: PDF 1724 views | ?

Davide Valentini¹, Martin Rao², Qingda Meng², Anna von Landenberg², Jiri Bartek Jr^3,4, Georges Sinclair⁴, Georgia Paraschoudi², Elke Jäger⁵, Inti Harvey-Peredo⁴, Ernest Dodoo⁴ and Markus Maeurer^1,2,5

¹ Centre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge, Stockholm, Sweden
² Therapeutic Immunology Unit (TIM), Department of Laboratory Medicine (LABMED), Karolinska Institutet, Stockholm, Sweden
³ Department of Neurosurgery, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
⁴ Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden
⁵ Krankenhaus Nordwest, Division of Oncology and Hematology, Frankfurt, Germany

Published: December 04, 2018

This article has been corrected: Please note the following IP filing: IP has been filed for the cytokine cocktail IL-2, IL-15 and IL-21 used for T-cell expansion.

Original article: Oncotarget. 2018; 9:19469-19480. DOI: https://doi.org/10.18632/oncotarget.24955.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26447

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma